Clinical trial

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

NCT07583511

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Teniposide Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Etoposide Normalized identity: etoposideView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention serplulimab Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record cisplatin Normalized identity: cisplatinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-02-01

PhasePHASE2

Conditions

Small-cell Lung Cancerunresolved

Interventions

TeniposideDRUG

EtoposideDRUG · verified · RxNorm: etoposide

serplulimabDRUG

cisplatinDRUG · verified · RxNorm: cisplatin

Sponsors & collaborators

Sun Yat-sen Universitylead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07583511 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.